BMS-790052 (daclatasvir)

daclatasvir · Bristol-Myers Squibb

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BMS-790052 (daclatasvir), covering 2015-09-07 to 2015-09-07. Get the full timeline:

Most recent: Clinical Trial Update: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C [Phase 3]